Document text
Principal Investigator: Liang Cao
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2021
Award: $1,530,925
Funding agency: National Cancer Institute
Related to the specific goals above, we conducted various studies to support biomarker driven early-stage drug development: 1. Application of new or novel biomarkers in early stage trials of highly unique therapeutic agents. A) We supported marker investigation of Dr. Andrea Apolo by investigating the drug effects on angiogenesis and inflammation. The work was recently published (Lancet Oncol. 21: 1099-1109, 2020). B) We provided biomarker analyses for an antiangiogenic therapy study by Dr. Jung-min Lee (Gynecol Oncol. 159: 88-94, 2020). C) We conducted the biomarkers studies in a trial by Dr. Vladimir Valera on an EpCAM antibody, vicinium, in combination with immunotherapy. In the study, we develop both PD and PK assays for the drug, as well as conduct immune cytokine profiling for the trial. Our results provided the first informative PK data on vicinium and the trial is on-going. D) We developed a cell free DNA detection for cervical cancer and use it for treatment monitoring, minimum residue disease (MRD) detection, cancer genotyping for patient selection. We support a number of HPV-targeted therapy trials by Dr. Christian Hinrichs, who is succeeded by Dr. Scott Norberg. We also successfully evaluated our assay in MRD monitoring of plasma somatic mutations in a checkpoint/vaccine study on prostate cancer. 2. Identification of new biomarkers. A) We worked with Dr. Ira Pastan and Raffit Hassan to uncover biomarkers for treatment monitoring and response prediction. The early results were published (JCO Precis Oncol. doi: 10.1200/PO.17.00282, 2018), and we continuously support a number of NCI trials by Dr. Hassan and Dr. Alewine on mesothelin-targeted agents. B). In working with Dr. Steven Pavletic, we developed new cytokine tests for the investigation of graft vs host disease (Am J Hematol. 95: 387-394, 2020 and Blood 137: 896-907, 2020). 3. Assay development and validation. A) We developed a new tumor antigen test and carried extensive analytic and clinical validation (J Appl Med Lab. 3:166-177, 2018), leading to the approval of the test by NCI Biomarker Committee for applications of multiple NCI-sponsored multicenter trials. We currently three multicenter trials with this test to assess its ability for treatment monitoring and patient selection. This test is also used to support various mesothelin-targeted antibody or T cell therapies by Dr. Raffit Hassan and Christine Alewine. B) We developed a cell free DNA for patient selection and treatment monitoring of HPV positive cancer patients on adoptive T cell therapies (Clin Cancer Res. 23:6856-6862, 2017). We have conducted a joint assay validation with Kite Pharma and have the assay transfer to their operation for treatment monitoring and patient selection. C) In response to COVID-19 pandemic, we developed a high-performance serology test for COVID-19. In addition, we also developed a test to evaluate an assay to evaluate the ACE2 receptor binding of various SARS-cov-2 variants. We generated extensive clinical data with donors who had COVID-19 or vaccination in collaboration with Dr. Kamille West of NIH Clinical Center. A manuscript was submitted for publication. 4. New technology development. A) We focus on the development of a circulating tumor DNA based technology for determining cancer gene mutations associated with treatment responses, and for the identification of mutations associated with resistance. We successfully developed new NGS-based assays to examine somatic mutations involved in the process of antigen presentation and T cell response using cell free DNA. The work is to support trials by Dr. Christian Hinrichs, who was succeeded by Dr. Scott Norberg. B) We are working on cell free DNA test for the investigation of potential neoplasia in pregnant women presented with abnormal NIPT test results in a trial led by Dr. Christina Annunziata and Dr. Diana Bianchi of NICHD.
Terms: <2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Angiogenesis Antagonists><Angiogenesis Blockers><Angiogenesis Inhibitors><Angiogenetic Antagonists><Angiogenetic Inhibitors><Angiogenic Antagonists><Angiogenic Inhibitors><Angiostatic Agents><Anti-Angiogenetic Agents><Anti-Angiogenic Agents><Anti-Angiogenic Drugs><Antiangiogenesis Agents><Antiangiogenic Agents><Antiangiogenic Drugs><Antibodies><Antigen Defined by Monoclonal Antibody AUAI><Antigen Presentation><Assay><Bioassay><Biologic Assays><Biological Assay><Biological Markers><Blood><Blood Plasma><Blood Reticuloendothelial System><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 public health crisis><COVID-19 test><COVID-19 tests><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 pandemic><COVID19 public health crisis><COVID19 test><COVID19 tests><CV-19><CV19><Cancer Gene Mutation><Cancer Patient><Cancers><Cervical Cancer><Cervix Cancer><Clinical><Clinical Data><Clinical Drug Development><Clinical Drug Testing/Development><Clinical Trials><Collaborations><Data><Detection><Development><Disease><Disorder><Dose><Drug Kinetics><Drugs><EpCAM><Epithelial Cellular Adhesion Molecule><Evaluation><Experimental Therapies><GA733-2><Gastrointestinal Tumor-Associated Antigen 2, 35-KD Glycoprotein><Genetic Alteration><Genetic Change><Genetic defect><Goals><GvHD><HPV><Homologous Wasting Disease><Human Papilloma Virus><Human Papillomavirus><Immune><Immune mediated therapy><Immune response><Immunes><Immunological response><Immunologically Directed Therapy><Immunotherapy><Infectious Human Wart Virus><Inflammation><Investigation><Investigational Therapies><Investigational Treatments><Joints><Laboratories><M4S1><MIC18><Malignant Cervical Neoplasm><Malignant Cervical Tumor><Malignant Neoplasm of the Cervix><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Cervix><Malignant Tumor of the Cervix Uteri><Malignant Tumor of the Prostate><Malignant Uterine Cervix Neoplasm><Malignant Uterine Cervix Tumor><Malignant neoplasm of cervix uteri><Malignant neoplasm of prostate><Malignant prostatic tumor><Manuscripts><Medication><Membrane Component, Chromosome 4, Surface Marker 1><Monitor><Multi-center trial><Multicenter Trials><Mutation><NICHD><NIH><National Institute of Child Health and Human Development><National Institute of Children's Health and Human Development><National Institutes of Health><Neoplasms><Neovascularization Inhibitors><Patient Monitoring><Patient Selection><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Performance><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacodynamics><Pharmacokinetics><Phase><Plasma><Plasma Serum><Pregnant Women><Process><Prostate CA><Prostate Cancer><Prostatic Cancer><Publications><Publishing><Resistance><Reticuloendothelial System, Serum, Plasma><Runt Disease><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-CoV-2 test><SARS-CoV-2 tests><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2 epidemic><SARS-CoV2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Scientific Publication><Selection for Treatments><Serology test><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Soluble Mpf/Mesothelin-Related Protein><Somatic Mutation><T cell based therapeutics><T cell based therapy><T cell response><T cell targeted therapeutics><T cell therapy><TACSTD1><TACSTD1 gene><TM-MKR><Technology><Test Result><Testing><Therapeutic><Therapeutic Agents><Tumor Antigens><Tumor Markers><Tumor-Associated Antigen><Tumor-Associated Calcium Signal Transducer 1><United States National Institutes of Health><Uterine Cervix Cancer><Vaccination><Validation><Work><adoptive T cell transfer><adoptive T-cell therapy><angiogenesis><angiotensin converting enzyme 2><angiotensin converting enzyme II><antiangiogenic><antigen based test><antigen test><assay development><base><bio-markers><biologic marker><biomarker><biomarker-driven><cancer antigens><cancer specific gene mutation><cell free DNA><cell free circulating DNA><clinical center><clinical development><clinical investigation><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 test><coronavirus disease 2019 tests><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><cytokine><developmental><drug development><drug/agent><early biomarkers><early detection biomarkers><early detection markers><expectant mother><expecting mother><experimental therapeutic agents><experimental therapeutics><genome mutation><genotyped patients><graft versus host disease><graft vs host disease><graft vs. host disease><host response><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><immunoresponse><malignancy><mesothelin><neoplasia><neoplasm/cancer><neoplastic growth><new marker><new technology><novel><novel biomarker><novel marker><novel technologies><operation><patient safety><predicting response><prediction of response><predictive response><predictor of response><pregnant mothers><receptor binding><receptor bound><resistant><response><response prediction><response to treatment><serology assay><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 test><severe acute respiratory syndrome coronavirus 2 tests><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><targeted agent><targeted drug trials><targeted pharmaceutical trials><targeted therapy trials><targeted treatment trials><tech development><technology development><therapeutic T-cell platform><therapeutic response><therapy selection><treatment response><tumor DNA><tumor biomarker><tumor cell DNA><tumor specific biomarker><tumor-specific DNA><tumor-specific antigen><vaccination study><vaccination trial><vaccine study><vaccine trial><wart virus>